PortalPublikationenMicrosatellite analysis in serum DNA as a diagnostic tool fo...

Microsatellite analysis in serum DNA as a diagnostic tool for distinction of patients with unknown pancreatic masses.

Standard

Microsatellite analysis in serum DNA as a diagnostic tool for distinction of patients with unknown pancreatic masses. / Wachowiak, Robin; Kaifi, Jussuf; Schwarzenbach, Heidi; Yekebas, Emre F.; Merkert, Petra; Schurr, Paulus; Hansen, Bente; Reichelt, Uta; Strate, Tim; Pantel, Klaus; Izbicki, Jakob R.

in: DIAGN MOL PATHOL, Jahrgang 16, Nr. 3, 3, 2007, S. 174-178.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wachowiak, R, Kaifi, J, Schwarzenbach, H, Yekebas, EF, Merkert, P, Schurr, P, Hansen, B, Reichelt, U, Strate, T, Pantel, K & Izbicki, JR 2007, 'Microsatellite analysis in serum DNA as a diagnostic tool for distinction of patients with unknown pancreatic masses.', DIAGN MOL PATHOL, Jg. 16, Nr. 3, 3, S. 174-178. <http://www.ncbi.nlm.nih.gov/pubmed/17721326?dopt=Citation>

APA

Wachowiak, R., Kaifi, J., Schwarzenbach, H., Yekebas, E. F., Merkert, P., Schurr, P., Hansen, B., Reichelt, U., Strate, T., Pantel, K., & Izbicki, J. R. (2007). Microsatellite analysis in serum DNA as a diagnostic tool for distinction of patients with unknown pancreatic masses. DIAGN MOL PATHOL, 16(3), 174-178. [3]. http://www.ncbi.nlm.nih.gov/pubmed/17721326?dopt=Citation

Vancouver

Wachowiak R, Kaifi J, Schwarzenbach H, Yekebas EF, Merkert P, Schurr P et al. Microsatellite analysis in serum DNA as a diagnostic tool for distinction of patients with unknown pancreatic masses. DIAGN MOL PATHOL. 2007;16(3):174-178. 3.

Bibtex

@article{9a45b4c3458546c2a60ff234d83ac2b2,
title = "Microsatellite analysis in serum DNA as a diagnostic tool for distinction of patients with unknown pancreatic masses.",
abstract = "The clinical distinction between cancer and chronic pancreatitis is difficult in patients with pancreatic masses. To test whether detection of aberrant serum DNA could assist in this important differential diagnosis, we tested a panel of 12 microsatellitemarkers from chromosomes 17p, 17q, 13q, 9p, 5q, and 2p in the blood of 35 pancreatic cancer patients, 22 patients with chronic pancreatitis, and 20 healthy individuals. An average of 2.8 loss of heterozygosity (LOH) was found in 32 of 35 cancer patients of whom 30 (86%) had 2 or more LOH. LOH was also found in 7 of 22 pancreatitis patients but all these patients had only 1 LOH. No LOH was detected in healthy donors of comparable age. These data suggest that LOH analysis may be a substantial help for diagnosing pancreatic masses. An extension of the panel, perhaps in combination with a better selection of markers may further improve this assay.",
author = "Robin Wachowiak and Jussuf Kaifi and Heidi Schwarzenbach and Yekebas, {Emre F.} and Petra Merkert and Paulus Schurr and Bente Hansen and Uta Reichelt and Tim Strate and Klaus Pantel and Izbicki, {Jakob R.}",
year = "2007",
language = "Deutsch",
volume = "16",
pages = "174--178",
journal = "DIAGN MOL PATHOL",
issn = "1052-9551",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

RIS

TY - JOUR

T1 - Microsatellite analysis in serum DNA as a diagnostic tool for distinction of patients with unknown pancreatic masses.

AU - Wachowiak, Robin

AU - Kaifi, Jussuf

AU - Schwarzenbach, Heidi

AU - Yekebas, Emre F.

AU - Merkert, Petra

AU - Schurr, Paulus

AU - Hansen, Bente

AU - Reichelt, Uta

AU - Strate, Tim

AU - Pantel, Klaus

AU - Izbicki, Jakob R.

PY - 2007

Y1 - 2007

N2 - The clinical distinction between cancer and chronic pancreatitis is difficult in patients with pancreatic masses. To test whether detection of aberrant serum DNA could assist in this important differential diagnosis, we tested a panel of 12 microsatellitemarkers from chromosomes 17p, 17q, 13q, 9p, 5q, and 2p in the blood of 35 pancreatic cancer patients, 22 patients with chronic pancreatitis, and 20 healthy individuals. An average of 2.8 loss of heterozygosity (LOH) was found in 32 of 35 cancer patients of whom 30 (86%) had 2 or more LOH. LOH was also found in 7 of 22 pancreatitis patients but all these patients had only 1 LOH. No LOH was detected in healthy donors of comparable age. These data suggest that LOH analysis may be a substantial help for diagnosing pancreatic masses. An extension of the panel, perhaps in combination with a better selection of markers may further improve this assay.

AB - The clinical distinction between cancer and chronic pancreatitis is difficult in patients with pancreatic masses. To test whether detection of aberrant serum DNA could assist in this important differential diagnosis, we tested a panel of 12 microsatellitemarkers from chromosomes 17p, 17q, 13q, 9p, 5q, and 2p in the blood of 35 pancreatic cancer patients, 22 patients with chronic pancreatitis, and 20 healthy individuals. An average of 2.8 loss of heterozygosity (LOH) was found in 32 of 35 cancer patients of whom 30 (86%) had 2 or more LOH. LOH was also found in 7 of 22 pancreatitis patients but all these patients had only 1 LOH. No LOH was detected in healthy donors of comparable age. These data suggest that LOH analysis may be a substantial help for diagnosing pancreatic masses. An extension of the panel, perhaps in combination with a better selection of markers may further improve this assay.

M3 - SCORING: Zeitschriftenaufsatz

VL - 16

SP - 174

EP - 178

JO - DIAGN MOL PATHOL

JF - DIAGN MOL PATHOL

SN - 1052-9551

IS - 3

M1 - 3

ER -